Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Neoplasms 19Endometrial Neoplasms 15Ovarian Neoplasms 11Carcinoma, Non-Small-Cell Lung 10Neoplasm Metastasis 7Squamous Cell Carcinoma of Head and Neck 6Uterine Cervical Neoplasms 5Head and Neck Neoplasms 5Breast Neoplasms 5Rectal Neoplasms 4Pancreatic Neoplasms 4Melanoma 4Lung Neoplasms 4Colonic Neoplasms 4Fallopian Tube Neoplasms 3Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Recurrence 2Osteosarcoma 2Multiple Myeloma 2Locally Advanced Rectal Cancer (LARC) 2Carcinoma, Renal Cell 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Carcinoma 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Turcot syndrome 1

Interventions

Dexamethasone 808Bortezomib 446Lenalidomide 430Cyclophosphamide 336Melphalan 250Calcium Dobesilate 236daratumumab 217pomalidomide 201carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67Prednisone 64dexamethasone 21-phosphate 63isatuximab 62elotuzumab 60auricularum 57Antilymphocyte Serum 55belantamab mafodotin 54Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Multiple Myeloma × dostarlimab × Clear all
NCT04126200 2026-05-06

DREAMM 5

GlaxoSmithKline

Phase 1/2 Active not recruiting
208 enrolled 5 charts
Plasma cell

Multiple Myeloma

NCT06655818 2025-03-03

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

GlaxoSmithKline

Phase 1/2 Terminated
4 enrolled 16 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡